作为拓酶II选择性抗癌剂的二因登皮里丁:设计,合成和结构-活性关系
Aarajana Shrestha1, Soo-Yeon Hwang2, Surendra Kunwar3
1College of Pharmacy, Yeungnam University, Gyeongsan 38541, Republic of Korea; Department of Pharmaceutical Sciences, University of Kentucky College of Pharmacy, Lexington, KY 40508, USA.
研究人员开发了新的di-indenopyridine化合物,以Topoisomerase II alpha (Topo IIα) 为向,作为抗癌剂. 化合物17可选择性地催化抑制Topo IIα,在没有Topo II毒素的毒性的情况下显示出显著的抗增殖作用.
科学领域:
- 药用化学 医学化学
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 托波异相酶是DNA拓学的关键酶,使它们成为癌症化疗的关键标.
- 拓酶II (Topo II) 催化抑制剂为Topo II毒素提供了有希望的替代品,可能减少心脏毒性和二次癌症等副作用.
研究的目的:
- 设计和合成新型的二因登皮里丁衍生物作为潜在的拓糖酶I (Topo I) 和拓糖酶IIα (Topo IIα) 抑制剂.
- 评估这些化合物对癌症细胞系的抗增殖活性.
- 描述最强大的抑制剂的作用机制.
主要方法:
- 合成23种混合二-因登皮里丁化合物.
- 在体外测试以确定Topo I和Topo IIα抑制活性.
- 基于细胞的测试来评估抗增殖效应.
- 生物物理测试 (EtBr 位移,可裂解复合体,彗星测试) 来阐明抑制机制.
主要成果:
- 大多数合成的化合物对Topo IIα比Topo I具有选择性.
- 化合物17在20μM时表现出100%的Topo IIα抑制和强大的抗增殖活性.
- 化合物17被确定为一种非间歇性催化Topo IIα抑制剂.
结论:
- 这项研究成功开发了基于二-因登皮里丁基架的强大的催化Topo IIα抑制剂.
- 在印丹环的4位处的特定替代物 (,,,,) 对于活性至关重要.
- 化合物17代表了开发具有更好的安全性概况的新型抗癌疗法的一个有希望的领先地位.
更多相关视频
07:20Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents
Published on: May 28, 2014
10:13Simple and Fast Rolling Circle Amplification-Based Detection of Topoisomerase 1 Activity in Crude Biological Samples
Published on: December 2, 2022
相关概念视频
DNA Topoisomerases
Types and Mechanism of action
Topoisomerases are divided into two main types. ...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Inhibition of Cdk Activity
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
